BPC-157
Body Protection Compound-157
BPC-157 is a synthetic gastric peptide extensively studied in animal models for tissue repair and gut healing. It has no completed human trials and is classified as an FDA Category 2 bulk drug substance.
Overview
BPC-157 (Body Protection Compound-157) is a synthetic peptide consisting of 15 amino acids. It is derived from a sequence found in human gastric juice and is classified as a gastric pentadecapeptide. BPC-157 has been the subject of extensive preclinical research — predominantly in animal models — exploring its potential roles in tissue repair, mucosal protection, and various wound-healing processes.
Despite growing interest from athletes, wellness communities, and some clinicians, BPC-157 has not been approved for human use by any regulatory authority. It has no completed randomized controlled trials in humans, and its safety profile in people remains largely unknown. The FDA has classified BPC-157 as a Category 2 bulk drug substance, restricting its use in pharmaceutical compounding.
Research context
The majority of BPC-157 research has been conducted in laboratory (in vitro) and animal (in vivo) settings. Preclinical studies have investigated its effects in areas including gastrointestinal mucosal healing and ulcer models, tendon, ligament, muscle, and bone injury models, inflammatory pathways and wound-healing mechanisms, and vascular and neurological injury models.
A 2025 systematic review in orthopedic sports medicine literature synthesized the available preclinical evidence and noted that while animal data show promise for musculoskeletal applications, clinical safety data in humans are extremely limited. Only a small number of pilot-scale human studies have been published, none of which are large-scale randomized controlled trials. No pharmaceutical company has initiated an FDA clinical trial program for BPC-157 as of early 2026, partly because the compound's naturally occurring sequence makes it difficult to patent.
Safety and regulatory framing
FDA Category 2 bulk drug substance; no human clinical trials completed
BPC-157 is not approved by the FDA for any human use. In 2023, the FDA placed BPC-157 on its Category 2 list, which means it cannot be used by compounding pharmacies to create compounded medications. The FDA has cited concerns about immunogenicity, peptide-related impurities, and a lack of adequate human safety data.
BPC-157 is prohibited by the World Anti-Doping Agency (WADA) under its S0 category (non-approved substances) and is listed on the U.S. Department of Defense Prohibited Dietary Supplement Ingredients list. Products sold as 'research chemicals' with BPC-157 are not subject to FDA quality standards. Regulations vary by country. Readers should consult a licensed healthcare provider before considering any unapproved substance.
References
- Sikiric P, et al. "Stable Gastric Pentadecapeptide BPC 157: Novel Therapy in Gastrointestinal Tract." Curr Pharm Des (2018) ↗Current Pharmaceutical Design
- Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review (PMC, 2025) ↗PMC / NLM
- FDA Bulk Drug Substances Used in Compounding — Category 2 List ↗FDA.gov
- USADA: BPC-157 — Experimental Peptide Creates Risk for Athletes ↗USADA
- OPSS: BPC-157 Fact Sheet (Department of Defense) ↗DoD / OPSS
Research information only
Peptide Daily is an informational resource only. Peptide research chemicals are not approved for human use by the FDA unless otherwise noted. Nothing on this site constitutes medical advice. Consult a qualified healthcare provider before using any peptide or research chemical.
New regulatory shifts matter as much as the peptide itself
Subscribe for editorial updates when major price moves, lab tests, or regulatory events affect the compounds you're tracking.
Weekly update
Get weekly peptide price intel
No spam, unsubscribe anytime.
Keep exploring the research context
TB-500
TB-500 is a synthetic fragment of thymosin beta-4, studied in preclinical and veterinary settings for tissue repair. It is not FDA-approved for human use and is WADA-prohibited.
GHK-Cu
GHK-Cu is a naturally occurring copper-binding tripeptide researched for collagen synthesis and wound healing. Topical forms appear in many cosmetic products; injectable use is not FDA-approved.